Literature DB >> 18987627

The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study.

Ariel Graff-Guerrero1, Romina Mizrahi, Ofer Agid, Heidi Marcon, Penny Barsoum, Pablo Rusjan, Alan A Wilson, Robert Zipursky, Shitij Kapur.   

Abstract

The dopamine D(2) receptors exist in two states: a high-affinity state (D(2)(high)) that is linked to second messenger systems, is responsible for functional effects, and exhibits high affinity for agonists; and a low-affinity state that is functionally inert and exhibits lower affinity for agonists. The dopamine D(3) receptors have high-affinity for agonist (eg dopamine) and the existence of the two affinity states is controversial. Although preclinical studies in animal models of psychosis have shown a selective increase of D(2)(high) as the common pathway to psychosis, the D(3) has been suggested to be involved in the pathophysiology of psychosis. We report the first study of the D(2)(high) and D(3) in schizophrenia using the novel PET radiotracer, [(11)C]-(+)-PHNO. We recruited 13 patients with schizophrenia-spectrum disorder amidst an acute psychotic episode, drug free for at least 2 weeks, and 13 age-sex-matched healthy controls. The binding potential no-displaceable (BP(ND)) was examine in the main regions of interest (caudate, putamen, ventral striatum, globus pallidus, substantia nigra, and anterior thalamus) and in a voxel-wise analysis. The BP(ND) between patients and controls was not different in any of the regions. The voxel-wise analysis did not reveal any difference and no correlations were found between the BP(ND) and positive and negative syndrome scale subscales. Our results do not find support for the hypothesis linking psychosis to a selective increase in D(2)(high) and/or D(3) in schizophrenia. It is possible that receptors with high affinity are not accessible by [(11)C]-(+)-PHNO because they are occupied by endogenous dopamine, a possibility that can be ruled out in future experiments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18987627     DOI: 10.1038/npp.2008.199

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  36 in total

1.  [3H]4-(dimethylamino)-N-(4-(4-(2-methoxyphenyl)piperazin-1-yl) butyl)benzamide: a selective radioligand for dopamine D(3) receptors. II. Quantitative analysis of dopamine D(3) and D(2) receptor density ratio in the caudate-putamen.

Authors:  Jinbin Xu; Babak Hassanzadeh; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2010-06       Impact factor: 2.562

2.  [(3)H]4-(Dimethylamino)-N-[4-(4-(2-methoxyphenyl)piperazin- 1-yl)butyl]benzamide, a selective radioligand for dopamine D(3) receptors. I. In vitro characterization.

Authors:  Jinbin Xu; Wenhua Chu; Zhude Tu; Lynne A Jones; Robert R Luedtke; Joel S Perlmutter; Mark A Mintun; Robert H Mach
Journal:  Synapse       Date:  2009-09       Impact factor: 2.562

Review 3.  Is schizophrenia a dopamine supersensitivity psychotic reaction?

Authors:  Mary V Seeman; Philip Seeman
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-10-12       Impact factor: 5.067

Review 4.  Agonist high- and low-affinity states of dopamine D₂ receptors: methods of detection and clinical implications.

Authors:  Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-12-09       Impact factor: 3.000

5.  Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia.

Authors:  Sarah A Eisenstein; Ryan Bogdan; Ling Chen; Stephen M Moerlein; Kevin J Black; Joel S Perlmutter; Tamara Hershey; Deanna M Barch
Journal:  J Psychiatr Res       Date:  2016-11-17       Impact factor: 4.791

6.  Selective overexpression of dopamine D3 receptors in the striatum disrupts motivation but not cognition.

Authors:  Eleanor H Simpson; Vanessa Winiger; Dominik K Biezonski; Iram Haq; Eric R Kandel; Christoph Kellendonk
Journal:  Biol Psychiatry       Date:  2013-12-05       Impact factor: 13.382

7.  Ventral striatum binding of a dopamine D2/3 receptor agonist but not antagonist predicts normal body mass index.

Authors:  Fernando Caravaggio; Sofia Raitsin; Philip Gerretsen; Shinichiro Nakajima; Alan Wilson; Ariel Graff-Guerrero
Journal:  Biol Psychiatry       Date:  2013-03-27       Impact factor: 13.382

8.  Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia.

Authors:  W Gordon Frankle; Jennifer Paris; Michael Himes; N Scott Mason; Chester A Mathis; Rajesh Narendran
Journal:  Biol Psychiatry       Date:  2017-12-07       Impact factor: 13.382

9.  Further evaluation of the carbon11-labeled D(2/3) agonist PET radiotracer PHNO: reproducibility in tracer characteristics and characterization of extrastriatal binding.

Authors:  Alice Egerton; Ella Hirani; Rabia Ahmad; David R Turton; Diana Brickute; Lula Rosso; Oliver D Howes; Sajinder K Luthra; Paul M Grasby
Journal:  Synapse       Date:  2010-04       Impact factor: 2.562

Review 10.  Pathway-Specific Dopamine Abnormalities in Schizophrenia.

Authors:  Jodi J Weinstein; Muhammad O Chohan; Mark Slifstein; Lawrence S Kegeles; Holly Moore; Anissa Abi-Dargham
Journal:  Biol Psychiatry       Date:  2016-03-31       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.